Tyrosine kinase inhibitors, low intensity chemotherapy and allohct for adults with Philadelphia-positive acute lymphoblastic leukemia. Results of the polish adult leukemia group (PALG) ALL7 protocol
Sebastian Giebel(The Maria Sklodowska-Curie National Research Institute of Oncology), Anna Czyż(Wroclaw Medical University), Monika Paluszewska, Anna Kopińska(Medical University of Silesia), Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi), Janusz Hałka(Wojskowy Instytut Medycyny Lotniczej), Agnieszka Piekarska(Gdańsk Medical University), Elżbieta Wiater(Copernicus Memorial Hospital), Edyta Cichocka(Nicolaus Copernicus University), Grzegorz Helbig(Medical University of Silesia), Elżbieta Patkowska(Institute for Transfusion Medicine), Katarzyna Brzeźniakiewicz‐Janus(University of Zielona Góra), Anna Szmigielska‐Kapłon(Medical University of Lodz), Krzysztof Gawroński(Medical University of Warsaw), Jarosław Piszcz(Medical University of Białystok), Tomasz Gromek(Medical University of Lublin), J Kwiatkowski(Lublin Oncology Center), Agnieszka Kopacz(University of Rzeszów), Aleksandra Butrym(Wroclaw Medical University), Marta Barańska(Poznan University of Medical Sciences), Marzena Wątek(Holy Cross University)
Cited by 0
Related Papers
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714